iCo Therapeutics Oral Amphotericin B Published in Leading Journal

    VANCOUVER, Feb. 18 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased
to announce that a manuscript discussing iCo's oral Amphotericin B (AmpB)
formulation ("iCo-009") has been published in a leading journal, the
"International Journal of Pharmaceutics". The paper illustrates iCo-009's
pronounced anti-fungal activity against Aspergillus fumigatus or Candida
albicans, two potentially lethal fungal infections.
    The publication is titled "Development and characterization of oral
lipid-based Amphotericin B formulations with enhanced drug solubility,
stability and antifungal activity in rats infected with Aspergillus fumigatus
or Candida albicans".
    Publication highlights: Treatment with iCo-009 significantly decreased
total fungal colony forming unit ("CFU") concentrations recovered in all the
organs added together by (greater than)80% compared to non-treated controls,
without significant changes in plasma creatinine levels in the Aspergillus
fumigatus infected rats. CFU concentrations are important measures of the
magnitude of fungal infection. Plasma creatinine levels are critical to
understanding renal function, a key concern with some existing Amphotericin B
intravenous formulations.
    In addition, iCo-009 significantly decreased kidney fungal CFU
concentrations by (greater than)75% at the 5 mg/kg dose and by (greater
than)95% at the 10 mg/kg dose compared to non-treated controls without
significant changes in the plasma creatinine levels in the Candida
albicans-infected rats.
    "To have iCo-009 once again highlighted in a leading peer-reviewed
journal provides further validation of the potential of iCo-009," stated
Andrew Rae, President & CEO of iCo Therapeutics. "These are two important
fungal models that lend us increasing confidence in the future success of the


    Wasan, E.K., et al., Development and characterization of oral lipid-based
Amphotericin B formulations with enhanced drug solubility, stability and
antifungal activity in rats infected with Aspergillus fumigatus or Candida
albicans. Int J Pharm (2009), doi:10.1016/j.ijpharm.2009.01.003. The paper is
currently in press and is available online through the International Journal
of Pharmaceutics' website.

    About iCo Therapeutics

    iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on
redosing or reformulating drugs with clinical history for new or expanded
indications. iCo has exclusive worldwide rights to three products, iCo-007, in
Phase I for the treatment of Diabetic Macular Edema, iCo-008, a product with
Phase II clinical history to be developed for severe ocular allergies, and
iCo-009, an oral formulation of Amphotericin B for sight and life -
threatening diseases. iCo-009 also represents a new drug delivery technology
with the potential to reprofile other parenteral administered drugs to the
oral route of administration. iCo Therapeutics trades on the TSX-Venture
exchange under the symbol "ICO". For more information, visit the company
website at: www.icotherapeutics.com

    No regulatory authority has approved or disapproved the content of this
    release. The TSX Venture Exchange does not accept responsibility for the
    adequacy or accuracy of this release.

    Forward Looking Statements

    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on iCo
Therapeutics' current beliefs as well as assumptions made by and information
currently available to iCo Therapeutics and relate to, among other things,
anticipated financial performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by iCo Therapeutics in its
public securities filings; actual events may differ materially from current
expectations. iCo Therapeutics disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

    %SEDAR: 00024061E

For further information:

For further information: Business Development: Dr. John Clement, CBO,
(778) 688-0644; Finance Contact: Mr. John Meekison, CFO, (604) 602-9414 x 224;
Investor/Media Contact: Frederica Bell, Corp. Devt., (604) 602-9414 x 228; B&D
Capital, Joanne Calverley, (604) 685-6465

Organization Profile

iCo Therapeutics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890